{
    "filename": "pdf.pdf",
    "content_type": "application/pdf",
    "file_size": 45243,
    "metadata": {
        "identifiers": {
            "doi": "10.1016/s1473-3099(20)30141-9",
            "arxiv": null,
            "isbn": null,
            "doc_id": null,
            "url": "http://www.thelancet.com/article/S1473309920301419/pdf"
        },
        "title": "Convalescent plasma as a potential therapy for COVID-19",
        "author": "Long Chen, Jing Xiong, Lei Bao, Yuan Shi",
        "date": 2020,
        "affiliations": [
            "Hospital of Chongqing Medical University, China (YBXM-2019-013). We declare no competing interests.",
            "Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation base of Child development and Critical Disorders; Children\u2019s Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China (LC, JX, LB, YS)"
        ],
        "journal": "The Lancet Infectious Diseases",
        "abstract": "Convalescent plasma or immunoglobulins have been used as a last resort to improve the survival rate of patients with SARS whose condition continued to deteriorate despite treatment with pulsed methylprednisolone. Moreover, several studies showed a shorter hospital stay and lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent plasma.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>\u2013<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>] In 2014, the use of convalescent plasma collected from patients who had recovered from Ebola virus disease was recommended by WHO as an empirical treatment during outbreaks.[<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>] A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015.6 In terms of patients with pandemic 2009 influenza A H1N1 (H1N1pdm09) virus infection, a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality (odds ratio 0\u00b720 [95% CI 0\u00b706\u20130\u00b769], p=0\u00b701) for patients treated with convalescent plasma.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>] Additionally, in a subgroup analysis, viral load after convalescent plasma treatment was significantly lower on days 3, 5, and 7 after intensive care unit admission. No adverse events were observed. A multicentre, prospective, double-blind, randomised controlled trial by Hung and colleagues showed that using convalescent plasma from patients who recovered from the influenza A H1N1pdm[<a class=\"ref-link\" id=\"c09\" href=\"#r09\">09</a>] virus infection to treat patients with severe influenza A H1N1 infection was associated with a lower viral load and reduced mortality within 5 days of symptom onset.[<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>] A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>] Another meta-analysis by Luke and colleagues identified eight studies involving 1703 patients with 1918 influenzapneumonia from 1918 to 1925 who received an infusion of influenza-convalescent human blood products, which showed a pooled absolute reduction of 21% (95% CI 15\u201327; p<0\u00b7001) in the overall crude casefatality rate at low risk of bias.[<a class=\"ref-link\" id=\"c10\" href=\"#r10\">10</a>]",
        "references": "@article{holshue2020a,\n  author = {Holshue, M.L. and DeBolt, C. and Lindquist, S.},\n  title = {First case of 2019 novel coronavirus in the United States},\n  journal = {N Engl J Med},\n  date = {2020-01},\n  note = {published online},\n  volume = {31},\n  url = {https://doi.org/10.1056/NEJMoa2001191.},\n  more-authors = {true},\n  language = {}\n}\n@article{lai2005a,\n  author = {Lai, S.T.},\n  title = {Treatment of severe acute respiratory syndrome},\n  journal = {Eur J Clin Microbiol Infect Dis},\n  date = {2005},\n  volume = {24},\n  pages = {583\u201391},\n  language = {}\n}\n@article{soo2004a,\n  author = {Soo, Y.O. and Cheng, Y. and Wong, R.},\n  title = {Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients},\n  journal = {Clin Microbiol Infect},\n  date = {2004},\n  volume = {10},\n  pages = {676\u201378},\n  more-authors = {true},\n  language = {}\n}\n@article{cheng2005a,\n  author = {Cheng, Y. and Wong, R. and Soo, Y.O.},\n  title = {Use of convalescent plasma therapy in SARS patients in Hong Kong},\n  journal = {Eur J Clin Microbiol Infect Dis},\n  date = {2005},\n  volume = {24},\n  pages = {44\u201346},\n  more-authors = {true},\n  language = {}\n}\n@article{arabi2015a,\n  author = {Arabi, Y. and Balkhy, H. and Hajeer, A.H.},\n  title = {Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol},\n  journal = {Springerplus},\n  date = {2015},\n  volume = {4},\n  pages = {709},\n  language = {}\n}\n@article{hung2011a,\n  author = {Hung, I.F. and To, K.K. and Lee, C.K.},\n  title = {Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection},\n  journal = {Clin Infect Dis},\n  date = {2011},\n  volume = {52},\n  pages = {447\u201356},\n  more-authors = {true},\n  language = {}\n}\n@article{hung2013a,\n  author = {Hung, I.F.N. and To, K.K.W. and Lee, C.K.},\n  title = {Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection},\n  journal = {Chest},\n  date = {2013},\n  volume = {144},\n  pages = {464\u201373},\n  more-authors = {true},\n  language = {}\n}\n@article{mair-jenkins2015a,\n  author = {Mair-Jenkins, J. and Saavedra-Campos, M. and Baillie, J.K.},\n  title = {The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis},\n  journal = {J Infect Dis},\n  date = {2015},\n  volume = {211},\n  pages = {80\u201390},\n  more-authors = {true},\n  language = {}\n}\n@article{luke2006a,\n  author = {Luke, T.C. and Kilbane, E.M. and Jackson, J.L. and Hoffman, S.L.},\n  title = {Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?},\n  journal = {Ann Intern Med},\n  date = {2006},\n  volume = {145},\n  pages = {599\u2013609},\n  language = {}\n}\n@article{schoofs2016a,\n  author = {Schoofs, T. and Klein, F. and Braunschweig, M.},\n  title = {HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1},\n  journal = {Science},\n  date = {2016},\n  volume = {352},\n  pages = {997\u20131001},\n  more-authors = {true},\n  language = {}\n}\n@article{lu2016a,\n  author = {Lu, C.L. and Murakowski, D.K. and Bournazos, S.},\n  title = {Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo},\n  journal = {Science},\n  date = {2016},\n  volume = {352},\n  pages = {1001\u201304},\n  more-authors = {true},\n  language = {}\n}\n@misc{clark-a,\n  author = {Clark, D.R. and Jonathan, E.M. and J.K.B.},\n  title = {Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; published online},\n  date = {Feb 7.},\n  url = {https://doi.org/10.1016/S0140-6736},\n  language = {}\n}\n",
        "links": [
            "https://doi.org/10.1016/",
            "http://apps.who.int/iris/rest/",
            "http://www.thelancet.com/infection",
            "https://www.who"
        ],
        "emails": [
            "petshi530@vip.163.com"
        ],
        "references_ris": "TY  - JOUR\nAU  - Holshue, M.L.\nAU  - DeBolt, C.\nAU  - Lindquist, S.\nTI  - First case of 2019 novel coronavirus in the United States\nT2  - N Engl J Med\nPY  - 2020\nDA  - 2020/01\nN1  - published online\nVL  - 31\nUR  - https://doi.org/10.1056/NEJMoa2001191.\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lai, S.T.\nTI  - Treatment of severe acute respiratory syndrome\nT2  - Eur J Clin Microbiol Infect Dis\nPY  - 2005\nDA  - 2005\nVL  - 24\nSP  - 583\nEP  - 91\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Soo, Y.O.\nAU  - Cheng, Y.\nAU  - Wong, R.\nTI  - Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients\nT2  - Clin Microbiol Infect\nPY  - 2004\nDA  - 2004\nVL  - 10\nSP  - 676\nEP  - 78\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Cheng, Y.\nAU  - Wong, R.\nAU  - Soo, Y.O.\nTI  - Use of convalescent plasma therapy in SARS patients in Hong Kong\nT2  - Eur J Clin Microbiol Infect Dis\nPY  - 2005\nDA  - 2005\nVL  - 24\nSP  - 44\nEP  - 46\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Arabi, Y.\nAU  - Balkhy, H.\nAU  - Hajeer, A.H.\nTI  - Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol\nT2  - Springerplus\nPY  - 2015\nDA  - 2015\nVL  - 4\nSP  - 709\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Hung, I.F.\nAU  - To, K.K.\nAU  - Lee, C.K.\nTI  - Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection\nT2  - Clin Infect Dis\nPY  - 2011\nDA  - 2011\nVL  - 52\nSP  - 447\nEP  - 56\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Hung, I.F.N.\nAU  - To, K.K.W.\nAU  - Lee, C.K.\nTI  - Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection\nT2  - Chest\nPY  - 2013\nDA  - 2013\nVL  - 144\nSP  - 464\nEP  - 73\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Mair-Jenkins, J.\nAU  - Saavedra-Campos, M.\nAU  - Baillie, J.K.\nTI  - The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis\nT2  - J Infect Dis\nPY  - 2015\nDA  - 2015\nVL  - 211\nSP  - 80\nEP  - 90\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Luke, T.C.\nAU  - Kilbane, E.M.\nAU  - Jackson, J.L.\nAU  - Hoffman, S.L.\nTI  - Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?\nT2  - Ann Intern Med\nPY  - 2006\nDA  - 2006\nVL  - 145\nSP  - 599\nEP  - 609\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Schoofs, T.\nAU  - Klein, F.\nAU  - Braunschweig, M.\nTI  - HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1\nT2  - Science\nPY  - 2016\nDA  - 2016\nVL  - 352\nSP  - 997\nEP  - 1001\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lu, C.L.\nAU  - Murakowski, D.K.\nAU  - Bournazos, S.\nTI  - Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo\nT2  - Science\nPY  - 2016\nDA  - 2016\nVL  - 352\nSP  - 1001\nEP  - 04\nC1  - true\nLA  - \nER  - \n\nTY  - GEN\nAU  - Clark, D.R.\nAU  - Jonathan, E.M.\nAU  - J.K.B.\nTI  - Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; published online\nPY  - Feb 7.\nDA  - Feb 7.\nUR  - https://doi.org/10.1016/S0140-6736\nLA  - \nER  - \n\n",
        "author_conclusions": [],
        "table_captions": [],
        "figure_captions": []
    },
    "sections": {
        "funding": [
            "This work is supported by grants from the Clinical Medical Study Program of Children\u2019s Hospital of Chongqing Medical University, China (YBXM-2019-013)"
        ],
        "introduction": [
            "This work is supported by grants from the Clinical Medical Study Program of Children\u2019s Hospital of Chongqing Medical University, China (YBXM-2019-013). We declare no competing interests.",
            "Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation base of Child development and Critical Disorders; Children\u2019s Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China (LC, JX, LB, YS)"
        ]
    },
    "structured_content": {},
    "participants": [
        {
            "participant": "studies",
            "number": 8,
            "context": "A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.9. <mark class=\"stats\">Another meta-analysis by Luke and colleagues identified eight studies involving 1703 patients with 1918 influenzapneumonia from 1918 to 1925 who received an infusion of influenza-convalescent human blood products, which showed a pooled absolute reduction of 21% (95% CI 15\u201327; p<0\u00b7001) in the overall crude casefatality rate at low risk of bias.10</mark>. "
        },
        {
            "participant": "people",
            "number": 77700,
            "context": "The pneumonia induced by the SARS-CoV-2 is named coronavirus disease 2019 (COVID-19). <mark class=\"stats\">By Feb 22, 2020, this virus has affected more than 77 700 people worldwide and caused more than 2300 deaths</mark>. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection"
        },
        {
            "participant": "studies",
            "number": 8,
            "context": "A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.9. <mark class=\"stats\">Another meta-analysis by Luke and colleagues identified eight studies involving 1703 patients with 1918 influenzapneumonia from 1918 to 1925 who received an infusion of influenza-convalescent human blood products, which showed a pooled absolute reduction of 21% (95% CI 15\u201327; p<0\u00b7001) in the overall crude casefatality rate at low risk of bias.10</mark>. One possible explanation for the efficacy of con\u00ad valescent plasma therapy is that the antibodies from convalescent plasma might suppress viraemia"
        }
    ],
    "statistics": [
        {
            "p_value": "p=0.01",
            "context": "In 2014, the use of convalescent plasma collected from patients who had recovered from Ebola virus disease was recommended by WHO as an empirical treatment during outbreaks.5. <mark class=\"stats\">A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015.6 In terms of patients with pandemic 2009 influenza A H1N1 (H1N1pdm09) virus infection, a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality (odds ratio 0\u00b720 [95% CI 0\u00b706\u20130\u00b769], p=0\u00b701) for patients treated with convalescent plasma.7</mark>. Additionally, in a subgroup analysis, viral load after convalescent plasma treatment was significantly lower on days 3, 5, and 7 after intensive care unit admission",
            "tests": {
                "tests": [
                    {
                        "test": "relative risk",
                        "value": "0\u00b720"
                    },
                    {
                        "test": "odds ratio",
                        "value": "0\u00b720"
                    }
                ]
            }
        },
        {
            "p_value": "p<0.001",
            "context": "A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.9. <mark class=\"stats\">Another meta-analysis by Luke and colleagues identified eight studies involving 1703 patients with 1918 influenzapneumonia from 1918 to 1925 who received an infusion of influenza-convalescent human blood products, which showed a pooled absolute reduction of 21% (95% CI 15\u201327; p<0\u00b7001) in the overall crude casefatality rate at low risk of bias.10</mark>. "
        },
        {
            "p_value": "p<0.001",
            "context": "A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.9. <mark class=\"stats\">Another meta-analysis by Luke and colleagues identified eight studies involving 1703 patients with 1918 influenzapneumonia from 1918 to 1925 who received an infusion of influenza-convalescent human blood products, which showed a pooled absolute reduction of 21% (95% CI 15\u201327; p<0\u00b7001) in the overall crude casefatality rate at low risk of bias.10</mark>. One possible explanation for the efficacy of con\u00ad valescent plasma therapy is that the antibodies from convalescent plasma might suppress viraemia"
        }
    ],
    "keywords": [
        "coronavirus",
        "convalescent plasma therapy",
        "meta analysis",
        "viral load",
        "adverse event",
        "virus infection",
        "chongqing medical university",
        "middle east respiratory syndrome coronavirus",
        "blood product",
        "HIV-1",
        "SARS",
        "child development",
        "novel coronavirus",
        "childrens hospital",
        "convalescent plasma treatment",
        "severe acute respiratory",
        "double blind",
        "H1N1"
    ],
    "keyword_relevance": {
        "SARS": 0.17647058823529413,
        "coronavirus": 0.13725490196078433,
        "HIV-1": 0.11764705882352941,
        "H1N1": 0.11764705882352941,
        "severe acute respiratory": 0.09803921568627451,
        "virus infection": 0.0784313725490196,
        "novel coronavirus": 0.0784313725490196,
        "adverse event": 0.058823529411764705,
        "convalescent plasma therapy": 0.0392156862745098,
        "viral load": 0.0392156862745098,
        "blood product": 0.0392156862745098,
        "convalescent plasma treatment": 0.0196078431372549,
        "meta analysis": 0.0,
        "chongqing medical university": 0.0,
        "middle east respiratory syndrome coronavirus": 0.0,
        "child development": 0.0,
        "childrens hospital": 0.0,
        "double blind": 0.0
    },
    "species": [],
    "summary": [
        "In the USA, the first patient infected with SARS-CoV-2 was treated by supportive care and intravenous remdesivir, before the patient recovered and was discharged.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] randomised clinical trials are needed to evaluate the safety and efficacy of remdesivir in the treatment of COVID-19.",
        "Several studies showed a shorter hospital stay and lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent plasma.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>\u2013<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>] In 2014, the use of convalescent plasma collected from patients who had recovered from Ebola virus disease was recommended by WHO as an empirical treatment during outbreaks.[<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>] A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015.6 In terms of patients with pandemic 2009 influenza A H1N1 (H1N1pdm09) virus infection, a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality for patients treated with convalescent plasma.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>] in a subgroup analysis, viral load after convalescent plasma treatment was significantly lower on days 3, 5, and 7 after intensive care unit admission.",
        "A multicentre, prospective, double-blind, randomised controlled trial by Hung and colleagues showed that using convalescent plasma from patients who recovered from the influenza A H1N1pdm[<a class=\"ref-link\" id=\"c09\" href=\"#r09\">09</a>] virus infection to treat patients with severe influenza A H1N1 infection was associated with a lower viral load and reduced mortality within 5 days of symptom onset.[<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>] A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>] Another meta-analysis by Luke and colleagues identified eight studies involving 1703 patients with 1918 influenzapneumonia from 1918 to 1925 who received an infusion of influenza-convalescent human blood products, which showed a pooled absolute reduction of 21% (95% CI 15\u201327; p<0\u00b7001) in the overall crude casefatality rate at low risk of bias.[<a class=\"ref-link\" id=\"c10\" href=\"#r10\">10</a>]",
        "The current guidelines emphasise that systematic corticosteroids should not be given routinely for the treatment of COVID-19, which was the recommendation in a a Commnt in The Lancet.[<a class=\"ref-link\" id=\"c14\" href=\"#r14\">14</a>] Evidence shows that convalescent plasma from patients who have recovered from viral infections can be used as a treatment without the occurrence of severe adverse events.",
        "Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks."
    ],
    "structured_summary": {
        "Introduction": [
            "In the USA, the first patient infected with SARS-CoV-2 was treated by supportive care and intravenous remdesivir, before the patient recovered and was discharged.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] randomised clinical trials are needed to evaluate the safety and efficacy of remdesivir in the treatment of COVID-19."
        ],
        "Results": [
            "Several studies showed a shorter hospital stay and lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent plasma.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>\u2013<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>] In 2014, the use of convalescent plasma collected from patients who had recovered from Ebola virus disease was recommended by WHO as an empirical treatment during outbreaks.[<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>] A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015.6 In terms of patients with pandemic 2009 influenza A H1N1 (H1N1pdm09) virus infection, a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality for patients treated with convalescent plasma.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>] in a subgroup analysis, viral load after convalescent plasma treatment was significantly lower on days 3, 5, and 7 after intensive care unit admission.",
            "A multicentre, prospective, double-blind, randomised controlled trial by Hung and colleagues showed that using convalescent plasma from patients who recovered from the influenza A H1N1pdm[<a class=\"ref-link\" id=\"c09\" href=\"#r09\">09</a>] virus infection to treat patients with severe influenza A H1N1 infection was associated with a lower viral load and reduced mortality within 5 days of symptom onset.[<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>] A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>] Another meta-analysis by Luke and colleagues identified eight studies involving 1703 patients with 1918 influenzapneumonia from 1918 to 1925 who received an infusion of influenza-convalescent human blood products, which showed a pooled absolute reduction of 21% (95% CI 15\u201327; p<0\u00b7001) in the overall crude casefatality rate at low risk of bias.[<a class=\"ref-link\" id=\"c10\" href=\"#r10\">10</a>]",
            "The current guidelines emphasise that systematic corticosteroids should not be given routinely for the treatment of COVID-19, which was the recommendation in a a Commnt in The Lancet.[<a class=\"ref-link\" id=\"c14\" href=\"#r14\">14</a>] Evidence shows that convalescent plasma from patients who have recovered from viral infections can be used as a treatment without the occurrence of severe adverse events."
        ],
        "Conclusion": [
            "Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks."
        ]
    },
    "reference_links": [
        {
            "id": "1",
            "alt_id": "Holshue_et+al_2020_a",
            "entry": "1 Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; published online Jan 31. https://doi.org/10.1056/NEJMoa2001191.",
            "crossref": "https://dx.doi.org/10.1056/NEJMoa2001191",
            "scite": "https://scite.ai/reports/10.1056/NEJMoa2001191",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1056/NEJMoa2001191"
        },
        {
            "id": "2",
            "alt_id": "Lai_2005_a",
            "entry": "2 Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis 2005; 24: 583\u201391.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lai%2C%20S.T.%20Treatment%20of%20severe%20acute%20respiratory%20syndrome%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lai%2C%20S.T.%20Treatment%20of%20severe%20acute%20respiratory%20syndrome%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lai%2C%20S.T.%20Treatment%20of%20severe%20acute%20respiratory%20syndrome%202005"
        },
        {
            "id": "3",
            "alt_id": "Soo_et+al_2004_a",
            "entry": "3 Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10: 676\u201378.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Soo%2C%20Y.O.%20Cheng%2C%20Y.%20Wong%2C%20R.%20Retrospective%20comparison%20of%20convalescent%20plasma%20with%20continuing%20high-dose%20methylprednisolone%20treatment%20in%20SARS%20patients%202004",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Soo%2C%20Y.O.%20Cheng%2C%20Y.%20Wong%2C%20R.%20Retrospective%20comparison%20of%20convalescent%20plasma%20with%20continuing%20high-dose%20methylprednisolone%20treatment%20in%20SARS%20patients%202004",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Soo%2C%20Y.O.%20Cheng%2C%20Y.%20Wong%2C%20R.%20Retrospective%20comparison%20of%20convalescent%20plasma%20with%20continuing%20high-dose%20methylprednisolone%20treatment%20in%20SARS%20patients%202004"
        },
        {
            "id": "4",
            "alt_id": "Cheng_et+al_2005_a",
            "entry": "4 Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24: 44\u201346.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Cheng%2C%20Y.%20Wong%2C%20R.%20Soo%2C%20Y.O.%20Use%20of%20convalescent%20plasma%20therapy%20in%20SARS%20patients%20in%20Hong%20Kong%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Cheng%2C%20Y.%20Wong%2C%20R.%20Soo%2C%20Y.O.%20Use%20of%20convalescent%20plasma%20therapy%20in%20SARS%20patients%20in%20Hong%20Kong%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Cheng%2C%20Y.%20Wong%2C%20R.%20Soo%2C%20Y.O.%20Use%20of%20convalescent%20plasma%20therapy%20in%20SARS%20patients%20in%20Hong%20Kong%202005"
        },
        {
            "id": "6",
            "alt_id": "Arabi_et+al_2015_a",
            "entry": "6 Arabi Y, Balkhy H, Hajeer AH. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus 2015; 4: 709.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Arabi%2C%20Y.%20Balkhy%2C%20H.%20Hajeer%2C%20A.H.%20Feasibility%2C%20safety%2C%20clinical%2C%20and%20laboratory%20effects%20of%20convalescent%20plasma%20therapy%20for%20patients%20with%20Middle%20East%20respiratory%20syndrome%20coronavirus%20infection%3A%20a%20study%20protocol%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Arabi%2C%20Y.%20Balkhy%2C%20H.%20Hajeer%2C%20A.H.%20Feasibility%2C%20safety%2C%20clinical%2C%20and%20laboratory%20effects%20of%20convalescent%20plasma%20therapy%20for%20patients%20with%20Middle%20East%20respiratory%20syndrome%20coronavirus%20infection%3A%20a%20study%20protocol%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Arabi%2C%20Y.%20Balkhy%2C%20H.%20Hajeer%2C%20A.H.%20Feasibility%2C%20safety%2C%20clinical%2C%20and%20laboratory%20effects%20of%20convalescent%20plasma%20therapy%20for%20patients%20with%20Middle%20East%20respiratory%20syndrome%20coronavirus%20infection%3A%20a%20study%20protocol%202015"
        },
        {
            "id": "7",
            "alt_id": "Hung_et+al_2011_a",
            "entry": "7 Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52: 447\u201356.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Hung%20IF%20To%20KK%20Lee%20CK%20et%20al%20Convalescent%20plasma%20treatment%20reduced%20mortality%20in%20patients%20with%20severe%20pandemic%20influenza%20A%20H1N1%202009%20virus%20infection%20Clin%20Infect%20Dis%202011%2052%2044756",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Hung%20IF%20To%20KK%20Lee%20CK%20et%20al%20Convalescent%20plasma%20treatment%20reduced%20mortality%20in%20patients%20with%20severe%20pandemic%20influenza%20A%20H1N1%202009%20virus%20infection%20Clin%20Infect%20Dis%202011%2052%2044756",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Hung%20IF%20To%20KK%20Lee%20CK%20et%20al%20Convalescent%20plasma%20treatment%20reduced%20mortality%20in%20patients%20with%20severe%20pandemic%20influenza%20A%20H1N1%202009%20virus%20infection%20Clin%20Infect%20Dis%202011%2052%2044756"
        },
        {
            "id": "8",
            "alt_id": "Hung_et+al_2013_a",
            "entry": "8 Hung IFN, To KKW, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144: 464\u201373.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Hung%20IFN%20To%20KKW%20Lee%20CK%20et%20al%20Hyperimmune%20IV%20immunoglobulin%20treatment%20a%20multicenter%20doubleblind%20randomized%20controlled%20trial%20for%20patients%20with%20severe%202009%20influenza%20AH1N1%20infection%20Chest%202013%20144%2046473",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Hung%20IFN%20To%20KKW%20Lee%20CK%20et%20al%20Hyperimmune%20IV%20immunoglobulin%20treatment%20a%20multicenter%20doubleblind%20randomized%20controlled%20trial%20for%20patients%20with%20severe%202009%20influenza%20AH1N1%20infection%20Chest%202013%20144%2046473",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Hung%20IFN%20To%20KKW%20Lee%20CK%20et%20al%20Hyperimmune%20IV%20immunoglobulin%20treatment%20a%20multicenter%20doubleblind%20randomized%20controlled%20trial%20for%20patients%20with%20severe%202009%20influenza%20AH1N1%20infection%20Chest%202013%20144%2046473"
        },
        {
            "id": "9",
            "alt_id": "Mair-Jenkins_et+al_2015_a",
            "entry": "9 Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211: 80\u201390.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Mair-Jenkins%2C%20J.%20Saavedra-Campos%2C%20M.%20Baillie%2C%20J.K.%20The%20effectiveness%20of%20convalescent%20plasma%20and%20hyperimmune%20immunoglobulin%20for%20the%20treatment%20of%20severe%20acute%20respiratory%20infections%20of%20viral%20etiology%3A%20a%20systematic%20review%20and%20exploratory%20meta-analysis%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Mair-Jenkins%2C%20J.%20Saavedra-Campos%2C%20M.%20Baillie%2C%20J.K.%20The%20effectiveness%20of%20convalescent%20plasma%20and%20hyperimmune%20immunoglobulin%20for%20the%20treatment%20of%20severe%20acute%20respiratory%20infections%20of%20viral%20etiology%3A%20a%20systematic%20review%20and%20exploratory%20meta-analysis%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Mair-Jenkins%2C%20J.%20Saavedra-Campos%2C%20M.%20Baillie%2C%20J.K.%20The%20effectiveness%20of%20convalescent%20plasma%20and%20hyperimmune%20immunoglobulin%20for%20the%20treatment%20of%20severe%20acute%20respiratory%20infections%20of%20viral%20etiology%3A%20a%20systematic%20review%20and%20exploratory%20meta-analysis%202015"
        },
        {
            "id": "10",
            "alt_id": "Luke_et+al_2006_a",
            "entry": "10 Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599\u2013609.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Luke%2C%20T.C.%20Kilbane%2C%20E.M.%20Jackson%2C%20J.L.%20Hoffman%2C%20S.L.%20Meta-analysis%3A%20convalescent%20blood%20products%20for%20Spanish%20influenza%20pneumonia%3A%20a%20future%20H5N1%20treatment%3F%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Luke%2C%20T.C.%20Kilbane%2C%20E.M.%20Jackson%2C%20J.L.%20Hoffman%2C%20S.L.%20Meta-analysis%3A%20convalescent%20blood%20products%20for%20Spanish%20influenza%20pneumonia%3A%20a%20future%20H5N1%20treatment%3F%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Luke%2C%20T.C.%20Kilbane%2C%20E.M.%20Jackson%2C%20J.L.%20Hoffman%2C%20S.L.%20Meta-analysis%3A%20convalescent%20blood%20products%20for%20Spanish%20influenza%20pneumonia%3A%20a%20future%20H5N1%20treatment%3F%202006"
        },
        {
            "id": "15",
            "alt_id": "Schoofs_et+al_2016_a",
            "entry": "15 Schoofs T, Klein F, Braunschweig M, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 2016; 352: 997\u20131001.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Schoofs%2C%20T.%20Klein%2C%20F.%20Braunschweig%2C%20M.%20HIV-1%20therapy%20with%20monoclonal%20antibody%203BNC117%20elicits%20host%20immune%20responses%20against%20HIV-1%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Schoofs%2C%20T.%20Klein%2C%20F.%20Braunschweig%2C%20M.%20HIV-1%20therapy%20with%20monoclonal%20antibody%203BNC117%20elicits%20host%20immune%20responses%20against%20HIV-1%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Schoofs%2C%20T.%20Klein%2C%20F.%20Braunschweig%2C%20M.%20HIV-1%20therapy%20with%20monoclonal%20antibody%203BNC117%20elicits%20host%20immune%20responses%20against%20HIV-1%202016"
        },
        {
            "id": "12",
            "alt_id": "Lu_et+al_2016_a",
            "entry": "12 Lu CL, Murakowski DK, Bournazos S, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 2016; 352: 1001\u201304.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lu%2C%20C.L.%20Murakowski%2C%20D.K.%20Bournazos%2C%20S.%20Enhanced%20clearance%20of%20HIV-1-infected%20cells%20by%20broadly%20neutralizing%20antibodies%20against%20HIV-1%20in%20vivo%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lu%2C%20C.L.%20Murakowski%2C%20D.K.%20Bournazos%2C%20S.%20Enhanced%20clearance%20of%20HIV-1-infected%20cells%20by%20broadly%20neutralizing%20antibodies%20against%20HIV-1%20in%20vivo%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lu%2C%20C.L.%20Murakowski%2C%20D.K.%20Bournazos%2C%20S.%20Enhanced%20clearance%20of%20HIV-1-infected%20cells%20by%20broadly%20neutralizing%20antibodies%20against%20HIV-1%20in%20vivo%202016"
        },
        {
            "id": "14",
            "alt_id": "Clark_et+al_Feb 7._a",
            "entry": "14 Clark DR, Jonathan EM, JKB. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; published online Feb 7. https://doi.org/10.1016/S0140-6736(20)30317-2.",
            "crossref": "https://dx.doi.org/10.1016/S0140-6736(20)30317-2",
            "scite": "https://scite.ai/reports/10.1016/S0140-6736(20)30317-2"
        }
    ],
    "facts": [
        "Convalescent plasma or immunoglobulins have been used as a last resort to improve the survival rate",
        "of patients with SARS whose condition continued to deteriorate despite treatment with pulsed methylprednisolone",
        "lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent plasma.2\u20134",
        "the use of convalescent plasma collected from patients who had recovered from",
        "Ebola virus disease was recommended by WHO as an empirical treatment",
        "a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality",
        "for patients treated with convalescent plasma.7 in a subgroup analysis",
        "viral load after convalescent plasma treatment was significantly lower on days 3",
        "A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses",
        "to 1925 who received an infusion of influenza-convalescent human blood products",
        "lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent",
        "for patients treated with convalescent plasma.[7",
        "randomised controlled trial by Hung and colleagues showed that using convalescent plasma from patients who recovered from the influenza",
        "The current guidelines emphasise that systematic corticosteroids should not be given",
        "Evidence shows that convalescent plasma from patients who have recovered from viral infections can be used as a treatment",
        "Use of convalescent whole blood or plasma collected from patients recovered from"
    ],
    "claims": [],
    "findings": [
        "A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015.6 In terms of patients with pandemic 2009 influenza A H1N1 (H1N1pdm09) virus infection, a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality (odds ratio 0\u00b720 [95% CI 0\u00b706\u20130\u00b769], p=0\u00b701) for patients treated with convalescent plasma.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>]",
        "A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>]. Another meta-analysis by Luke and colleagues identified eight studies involving 1703 patients with 1918 influenzapneumonia from 1918 to 1925 who received an infusion of influenza-convalescent human blood products, which showed a pooled absolute reduction of 21% (95% CI 15\u201327; p<0\u00b7001) in the overall crude casefatality rate at low risk of bias.[<a class=\"ref-link\" id=\"c10\" href=\"#r10\">10</a>]"
    ],
    "processes": [],
    "key_statements": [
        "A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015.6 In terms of patients with pandemic 2009 influenza A H1N1 (H1N1pdm09) virus infection, a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality for patients treated with convalescent plasma.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>]",
        "In a subgroup analysis, viral load after convalescent plasma treatment was significantly lower on days 3, 5, and 7 after intensive care unit admission",
        "A multicentre, prospective, double-blind, randomised controlled trial by Hung and colleagues showed that using convalescent plasma from patients who recovered from the influenza A H1N1pdm[<a class=\"ref-link\" id=\"c09\" href=\"#r09\">09</a>] virus infection to treat patients with severe influenza A H1N1 infection was associated with a lower viral load and reduced mortality within 5 days of symptom onset.[<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>]",
        "A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015.6 In terms of patients with pandemic 2009 influenza A H1N1 (H1N1pdm09) virus infection, a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality for patients treated with convalescent plasma.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>]",
        "A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>]"
    ],
    "top_statements": [
        "A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015.6 In terms of patients with pandemic 2009 influenza A H1N1 (H1N1pdm09) virus infection, a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality for patients treated with convalescent plasma.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>]",
        "In a subgroup analysis, viral load after convalescent plasma treatment was significantly lower on days 3, 5, and 7 after intensive care unit admission",
        "A multicentre, prospective, double-blind, randomised controlled trial by Hung and colleagues showed that using convalescent plasma from patients who recovered from the influenza A H1N1pdm[<a class=\"ref-link\" id=\"c09\" href=\"#r09\">09</a>] virus infection to treat patients with severe influenza A H1N1 infection was associated with a lower viral load and reduced mortality within 5 days of symptom onset.[<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>]",
        "A meta-analysis by Mair-Jenkins and colleagues showed that the mortality was reduced after receiving various doses of convalescent plasma in patients with severe acute respiratory infec\u00ad tions, with no adverse events or complications after treatment.[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>]"
    ],
    "headline": "A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015.6 In terms of patients with pandemic 2009 influenza A H1N1 virus infection, a prospective cohort study by Hung and colleagues showed a significant reduction in the relative risk of mortality for patients treated with convalescent plasma.7",
    "contexts": [],
    "abbreviations": {
        "nCoV": "novel coronavirus"
    }
}
